Keywords: Sanofi-Aventis, CureDM, Pancreate, type 1 and 2 diabetes, License

Sanofi-Aventis buys global rights to CureDM’s Pancreate for up to $355 million

Article | 08 April 2010

Print This

French drug major Sanofi-Aventis has entered into a licensing deal with USA-based CureDM on a novel human peptide, Pancreate, which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in